To review the pharmacology, efficacy, and safety of capivasertib for the treatment of adults with hormone receptor-positive, HER2-negative (HR+/HER2–) locally advanced or metastatic breast cancer with 1 or more PIK3CA/AKT1/PTEN alterations.
Data sources:
A literature search was conducted using PubMed and MEDLINE databases, published abstracts, and studies from ClinicalTrials.gov between 2003 and February 2024. Keywords included capivasertib, AZD5363, PI3K/AKT/mTOR pathway, and breast cancer.
Data extraction:
All applicable publications, package inserts, meeting abstracts, and clinical trials with capivasertib were reviewed.
Data synthesis:
Capivasertib is a first-in-class inhibitor of 3 isoforms of AKT (AKT-1, AKT-2, and AKT-3) which is an essential component in the PI3K/AKT/mTOR signaling pathway involved in oncogenesis. In the phase III CAPItello-291 trial, capivasertib in combination with fulvestrant (C+F) demonstrated improved progression-free survival (PFS) (7.3 vs 3.1 months) compared with placebo-fulvestrant (P+F) cohort in AKT-altered pathway patients who had progressed through prior aromatase inhibitor. The most common adverse reactions of any grade reported in the C+F group were diarrhea, cutaneous skin reactions, nausea, fatigue, and vomiting.
Relevance to patient care and clinical practice in comparison with existing drugs:
HR+/HER2– advanced breast cancer patients experience progression following endocrine therapies and cyclin-dependent kinase (CDK) 4/6 inhibitors. Capivasertib is a viable treatment option for patients with PIK3CA/AKT1/PTEN activating mutations following progression on endocrine-based regimens in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.
Conclusion:
Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.
ScheidemannERShajahan-HaqAN.Resistance to CDK4/6 Inhibitors in estrogen receptor-positive breast cancer. Int J Mol Sci. 2021;22(22):12292. doi:10.3390/ijms222212292
4.
RashaFSharmaMPruittK.Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol. 2021;532:111322. doi:10.1016/j.mce.2021.111322
5.
WanderSACohenOGongX, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 Inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10(8):1174-1193. doi:10.1158/2159-8290.CD-19-1390
6.
CostaCWangYLyA, et al. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3K alpha inhibitors in breast cancer. Cancer Discov. 2020;10(1):72-85. doi:10.1158/2159-8290.CD-18-0830
7.
PereiraBChinSFRuedaOM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. doi:10.1038/ncomms11479
8.
AndreFCiruelosERubovszkyG, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904
9.
PiccartMHortobagyiGNCamponeM, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357-2362. doi:10.1093/annonc/mdu456
ShariatiMMeric-BernstamF.Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019;28(11):977-988. doi:10.1080/13543784.2019.1676726
12.
BasuALambringCB.Akt isoforms: a family affair in breast cancer. Cancers. 2021;13(14):3445. doi:10.3390/cancers13143445
13.
CrouthamelMCKahanaJAKorenchukS, et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res. 2009;15(1):217-225. doi:10.1158/1078-0432.CCR-08-1253
14.
AddieMBallardPButtarD, et al. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem. 2013;56(5):2059-2073. doi:10.1021/jm301762v
15.
DaviesBRGreenwoodHDudleyP, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11(4):873-887. doi:10.1158/1535-7163.MCT-11-0824-T
16.
RibasRPancholiSGuestSK, et al. AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo. Mol Cancer Ther. 2015;14(9):2035-2048. doi:10.1158/1535-7163.MCT-15-0143
17.
YatesJWDudleyPChengJD’CruzCDaviesBR.Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. Cancer Chemother Pharmacol. 2015;76(2):343-356. doi:10.1007/s00280-015-2795-7
18.
BanerjiUDeanEJPerez-FidalgoJA, et al. A Phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res. 2018;24(9):2050-2059. doi:10.1158/1078-0432.CCR-17-2260
19.
TamuraKHashimotoJTanabeY, et al. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(4):787-795. doi:10.1007/s00280-016-2987-9
20.
DeanEBanerjiUSchellensJHM, et al. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. Cancer Chemother Pharmacol. 2018;81(5):873-883. doi:10.1007/s00280-018-3558-z
21.
Truqap (capivasertib). AstraZeneca, Inc.; 2023.
22.
MillerCSommavillaRMurphyDMorrisTKhatunMCullbergM.The effect of food and acid-reducing agents on the pharmacokinetic profile of capivasertib: results from a randomized, crossover study. Br J Clin Pharmacol. 2023;89(11):3330-3339. doi:10.1111/bcp.15831
23.
MillerCSommavillaRBarryST, et al. Pharmacokinetics of the Akt serine/threonine protein kinase Inhibitor, capivasertib, administered to healthy volunteers in the presence and absence of the CYP3A4 inhibitor itraconazole. Clin Pharmacol Drug Dev. 2023;12(9):856-862. doi:10.1002/cpdd.1307
24.
SmythLMTamuraKOliveiraM, et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer. Clin Cancer Res. 2020;26(15):3947-3957. doi:10.1158/1078-0432.CCR-19-3953
25.
JonesRHCasbardACarucciM, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21(3):345-357. doi:10.1016/S1470-2045(19)30817-4
26.
SchmidPAbrahamJChanS, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2020;38(5):423-433. doi:10.1200/JCO.19.00368
27.
MoseleFStefanovskaBLusqueA, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377-386. doi:10.1016/j.annonc.2019.11.006
28.
TurnerNCKingstonBKilburnLS, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21(10):1296-1308. doi:10.1016/S1470-2045(20)30444-7
29.
TurnerNCAlarconEArmstrongAC, et al. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol. 2019;30(5):774-780. doi:10.1093/annonc/mdz086
30.
KalinskyKHongFMcCourtCK, et al. Effect of Capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. JAMA Oncol. 2021;7(2):271-278. doi:10.1001/jamaoncol.2020.6741
31.
HowellSJCasbardACarucciM, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022;23(7):851-864. doi:10.1016/S1470-2045(22)00284-4
32.
TurnerNCOliveiraMHowellSJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070. doi:10.1056/NEJMoa2214131
33.
HamiltonENevenPPistilliB, et al. Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292. Abstract PS12-09. Paper presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. San Antonio, TX.
